Sharps Technology, Inc. is a medical device company that has designed and patented various safety syringes and is seeking to commercialize them. We were incorporated under the laws of the State of Nevada in the first quarter of 2022. Sharps was incorporated to purchase, develop, and commercialize a body of intellectual property resulting in a family of smart safety syringe products. Sharps closed the acquisition of this intellectual property in the fourth quarter of 2017. The intellectual property we purchased consisted of issued patent and patent files, new designs and iterations, samples, regulatory files, manufacturing files, product testing files, and market research files relating to such safety syringe products.
Company profile
Ticker
STSS
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
823751728
STSS stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
29 Mar 24
8-K
Entry into a Material Definitive Agreement
8 Mar 24
8-K
Regulation FD Disclosure
7 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
8-K
Sharps Technology Signs LOI with Roncadelle Operations Intended to Open Worldwide Sales and Distribution Opportunities for Safe Drug Delivery Systems
18 Jan 24
8-K
Changes in Registrant's Certifying Accountant
22 Dec 23
8-K
Departure of Directors or Certain Officers
20 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
DEF 14A
Definitive proxy
7 Nov 23
PRE 14A
Preliminary proxy
27 Oct 23
Latest ownership filings
4
Robert Michael Hayes
21 Feb 24
SC 13G
Walleye Capital LLC
14 Feb 24
4
Robert Michael Hayes
7 Feb 24
4
Robert Michael Hayes
5 Feb 24
SC 13G
Empery Asset Management, LP
9 Jan 24
4
Timothy James Ruemler
4 Jan 24
4
Andrew R. Crescenzo
29 Dec 23
4
Timothy James Ruemler
22 Dec 23
4
Timothy James Ruemler
27 Nov 23
4
Timothy James Ruemler
24 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.55 mm | 5.55 mm | 5.55 mm | 5.55 mm | 5.55 mm | 5.55 mm |
Cash burn (monthly) | (no burn) | 69.62 k | 786.12 k | 835.44 k | 671.31 k | 682.26 k |
Cash used (since last report) | n/a | 464.43 k | 5.24 mm | 5.57 mm | 4.48 mm | 4.55 mm |
Cash remaining | n/a | 5.09 mm | 310.18 k | -18.83 k | 1.08 mm | 1.00 mm |
Runway (months of cash) | n/a | 73.1 | 0.4 | -0.0 | 1.6 | 1.5 |
Institutional ownership, Q3 2023
32.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 16 |
Opened positions | 5 |
Closed positions | 4 |
Increased positions | 3 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 1.15 bn |
Total shares | 5.02 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Walleye Capital | 2.16 mm | $703.08 mm |
Armistice Capital | 1.18 mm | $124.07 mm |
Warberg Asset Management | 492.76 k | $51.99 mm |
Hudson Bay Capital Management | 470.00 k | $49.59 mm |
Ayrton Capital | 235.20 k | $24.81 mm |
HighTower Advisors | 120.80 k | $67.00 mm |
Clear Street | 117.78 k | $12.00 k |
ORG Partners | 100.05 k | $55.47 mm |
Compass Ion Advisors | 57.14 k | $31.68 mm |
Geode Capital Management | 41.18 k | $22.83 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Feb 24 | Robert Michael Hayes | Common Stock | Buy | Acquire P | No | No | 0.34 | 10,000 | 3.40 k | 95,882 |
6 Feb 24 | Robert Michael Hayes | Common Stock | Buy | Acquire P | No | No | 0.29 | 10,000 | 2.90 k | 85,882 |
2 Feb 24 | Robert Michael Hayes | Common Stock | Buy | Acquire P | No | No | 0.35 | 8,000 | 2.80 k | 75,882 |
31 Jan 24 | Robert Michael Hayes | Common Stock | Buy | Acquire P | No | No | 0.39 | 1,000 | 390.00 | 67,882 |
31 Jan 24 | Robert Michael Hayes | Common Stock | Buy | Acquire P | No | No | 0.38 | 1,200 | 456.00 | 66,882 |
3 Jan 24 | Timothy James Ruemler | Common Stock | Buy | Acquire P | No | No | 0.4 | 5,000 | 2.00 k | 1,061,675 |
2 Jan 24 | Timothy James Ruemler | Common Stock | Buy | Acquire P | No | No | 0.4 | 4,466 | 1.79 k | 1,056,675 |
28 Dec 23 | Andrew R. Crescenzo | Common Stock | Buy | Acquire P | No | No | 0.4216 | 3,500 | 1.48 k | 15,500 |
News
Earnings Scheduled For April 1, 2024
1 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
20 Mar 24
Sharps Technology Enters Latin American Market And Receives First Orders For Securegard Disposable Smart Safety Syringes From Strategic Distribution Partner In Colombia
21 Feb 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
6 Feb 24
Better Choice Company And 2 Other Stocks Under $3 Insiders Are Buying
6 Feb 24
Press releases
Sharps Technology's Global Expansion: Achieving Key Milestones To Strengthen Market Position
3 Apr 24
Sharps Technology Enters Latin American Market and Receives First Orders for Securegard Disposable Smart Safety Syringes from Strategic Distribution Partner in Colombia
21 Feb 24
Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems
16 Feb 24